Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Colchicine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,585 records · Page 88Linked to original sources

Colchicine for recurrent pericarditis in children.

The incidence of recurrence of acute pericarditis in children varies from 15% to 30% and is accompanied by a high morbidity. Various treatment modalities have been used with variable success rates and side effects. La Serna et al. (Lancet 1987; 26: 1517) were the first to treat adults with recurrent pericarditis with colchicine, and were followed by other authors. To our knowledge no studies in children have been reported. In this paper, we present three children who suffered from viral or idiopathic recurrent pericarditis, despite multiple courses of non-steroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids. They responded remarkably well to colchicine, which was administered for 6 months with no adverse reactions. They continue to do well 18, 11 and 12 months after cessation of treatment, respectively.

Adolescent↗

Docking study of ligands into the colchicine binding site of tubulin.

Cancer is a major cause of mortality in developed countries, following only cardiovascular diseases. Death of cancerous cells can be achieved by stopping mitosis and the antimitotic class of drugs formed by the spindle poisons can be used for this purpose. Their role is to disorganize the mitotic spindle by targeting its main constituent, the microtubules, themselves made of heterodimers of alpha and beta-tubulin. They disrupt the dynamics of the microtubules either by stabilizing them, as do paclitaxel or epothilones, or destabilizing them, as do colchicine. The binding site of colchicine seems to lie between the two units of the tubulin dimer. Here, we report on the characterization of this site by the docking of a series of reference compounds, and the subsequent docking of ligands prepared in our laboratory.

Animals↗

Permanent improvement of renal dysfunction and proteinuria with colchicine in a patient with tumoral amyloidosis and basal cell carcinoma.

Basal cell carcinoma and amyloid deposition was reported not uncommonly, but renal failure and nephrotic syndrome were rare. Here in, we reported a 72 years old male patient with nephrotic syndrome, renal failure and relatively small basal cell carcinoma. In this patient toumoral excision caused temporary improvement. When the proteinuria reappeared, due to amyloid deposition in toumoral tissue, colchicine was began. With colchicine therapy permanent improvement of nephrotic syndrome was achieved in follow-up 18 months.

Aged↗

The mechanism of action of colchicine. Binding of colchincine-3H to cellular protein.

The majority of the colchicine-(3)H bound by tissue culture cells (KB or Hela) was found to be present as a noncovalent complex with a macromolecule which appears in the soluble fraction after homogenization. Similar binding was demonstrated in vitro and was confined to a component of the soluble fraction. The binding-equilibrium constant and the kinetic constants were essentially the same in vivo and in vitro. Bound radioactivity was reisolated and shown to be present in a molecule with the same chromatographic behavior and specific antimitotic activity as colchicine. In vitro assay of binding activity of a variety of cells and tissues showed a correlation with the presence of microtubules. High binding activity was given by dividing cells, mitotic apparatus, cilia, sperm tails, and brain tissue. Binding to extracts of slime mold or to purified muscle proteins was very low or undetectable. The binding site had a sedimentation constant of 6S and it is suggested that the protein is a subunit of microtubules.

Animals↗

The role of three cytoplasmic fibers in BHK-21 cell motility. I. Microtubules and the effects of colchicine.

Microtubule breakdown in the presence of 5 or 40 microg/ml of colchicine is observed in BHK-21/C13 fibroblast-like cells. Several morphological and physiological effects are noted in the absence of microtubules: (a) the cells transform from fibroblast-like to epithelial-like cells; (b) the normal pattern of intracellular birefringence changes and a juxtanuclear cap of birefringent filaments is formed; (c) time-lapse cinematography demonstrates that cell locomotion is inhibited in colchicine-treated cells, even though membrane ruffling persists. The results are discussed in terms of the specific roles of microtubules in cultured cell motility and possible functional relationships of the three types of cytoplasmic fibers seen in BHK-21 cells.

Animals↗

Mechanisms of lysosomal enzyme release from human leukocytes. I. Effect of cyclic nucleotides and colchicine.

In order to study mechanisms underlying selective enzyme release from human leukocytes during phagocytosis, the effects were studied of compounds which affect microtubule integrity or the accumulation of cyclic nucleotides. Human leukocytes selectively extrude lysosomal enzymes (beta-glucuronidase) from viable cells during phagocytosis of zymosan or immune complexes, or upon encounter with immune complexes dispersed along a non-phagocytosable surface such as a millipore filter. In each circumstance, lysosomal enzyme release was reduced by previous treatment of cells with pharmacological doses of drugs which disrupt microtubules (e.g. 10(-3)-10(-5) M colchicine) or with agents which affect accumulation of adenosine 3'5'-monophosphate (cAMP) (e.g. 10(-3) M cyclic nucleotides and 2.8 x 10(-4)-2.8 x 10(-6) M prostaglandin E (PGE) and A (PGA) compounds). Preincubation of cells with 5 microg/ml cytochalasin B resulted in complete inhibition of zymosan ingestion, but not of adherence of zymosan particles to plasma membranes or selective enzyme release. In this system, in which enzyme release was independent of particle uptake, preincubation of cells with colchicine, vinblastine, dibutyryl cAMP, or PGE(1) also reduced extrusion of lysosomal enzymes. When cell suspensions were incubated with membrane-lytic crystals of monosodium urate (MSU), cytoplasmic as well as lysosomal enzymes were released with subsequent death of the cells. However, enzyme release followed phagocytosis of crystals (as measured by enhanced C-1 oxidation of glucose) and was due to "perforation from within" of the lysosomal membrane, rather than lysis by crystals of the plasma membrane. Enzyme release after MSU ingestion was also reduced when cells were treated with pharmacological doses of the test agents. When cells were killed by Triton X-100, acting on the plasma membrane, C-1 oxidation of glucose was abolished and enzyme release could not be inhibited pharmacologically. These observations suggest that lysosomal enzyme release from human phagocytes can be an active process which accompanies plasma membrane stimulation, is independent of cell death, and may be controlled by cyclic nucleotides and agents which affect microtubules.

Arthritis, Rheumatoid↗

Induction and mode of action of suppressor cells generated against human gamma globulin. II. Effects of colchicine.

The ability of colchicine (Col) to interfere with suppressor cells specific for the soluble protein antigen human gamma globulin (HGG) has been examined. This interference may be the mechanism of the adjuvanticity promoted by Col. When injected into A/J mice at the appropriate time and concentration, both Col and cyclophosphamide promoted an adjuvant increase in the plaque-forming cell response to 100 micrograms of immunogenic, aggregated HGG. Col abrogated both the induction of suppressor cells when injected with 3 h of tolerization with deaggregated (DHGG) and the expression of previously induced suppressor cells when injected with the antigenic challenge. Interference with the generation and expression of antigen-specific suppressor cells had no detectable effects on the immunologic unresponsive state to HGG. Col did not interfere with the induction of tolerance at a dose (1 mg/kg) that abolished the generation of suppressor cells. Furthermore, the absence of colchicine-sensitive-suppressor cells during the establishment of tolerance had no observable effect on the duration of unresponsivness in either helper T- or B-lymphocyte populations. Finally, Col was not able to terminate the unresponsive state established by DHGG even when responsive splenic B cells could be demonstrated in tolerant animals. These data indicate that suppressor cells are not required for the establishment and maintenance of the unresponsive state to this antigen.

Adjuvants, Immunologic↗

A case of recurrent benign pericarditis treated by colchicine.

After five recurrences of idiopathic pericarditis over a period of 8 months on steroidal anti-inflammatory therapy, a splenectomized patient aged 31 years benefited from treatment with colchicine. He was treated for one year without any recurrence. A relapse occurred 6, 7 and 17 months after having stopped the drug. This observation raises the question whether colchicine might be beneficial in recurrent benign pericarditis with or without corticodependence and have a prophylactic action against recurrences.

Adult↗

Colchicine poisoning: report of a fatal case and presentation of an HPLC procedure for body fluid and tissue analyses.

A case involving a suicidal overdose resulting from the ingestion of colchicine tablets is presented. The drug was quantitated using liquid chromatography. The femoral blood level was 62 ng/mL, and the maximum concentration found in bile was 2921 ng/mL. Therefore, bile appears to be the sample of choice for toxicological analysis when a poisoning case involving colchicine is suspected.

Adult↗

A fatal overdose with colchicine.

A colchicine blood concentration 250 microgram/L was determined in a 39-year-old white female 2 hours following the ingestion of an oral overdose of the drug. At death, 40 hours following ingestion, no drug was detected. Colchicine was extracted from buffered blood using dichloromethane. The evaporated extract was redissolved in 0.1 N HCl and analyzed using a high performance liquid chromatograph equipped with an octadecylsilane reversed phase column.

Adult↗

Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine, and adriamycin.

A noncloned subline of 3T3FL cells was developed that was resistant to the toxicity of the ansamycin alkaloid maytansine. Culture of 3T3FL cells with serially increasing concentrations of maytansine resulted in a cell line resistant to maytansine at concentrations 118-fold higher than concentrations cytotoxic for parental cells. Resistant cells (3T3r) exhibited cross-resistance to colchicine, vincristine, adriamycin, and, to a lesser extent, cytochalasin B. Studies of binding and uptake of tritiated colchicine suggested that drug resistance of 3T3r cells might reflect decreased uptake of drug without decreased binding to surface receptors. Murine sarcoma virus transformed 3T3r cells less efficiently than 3T3FL cells.

Animals↗

Detection of chromosome 2 and chromosome 7 within X-ray- or colchicine-induced micronuclei by fluorescence in situ hybridization.

The occurrence of chromosome 2 and chromosome 7 within micronuclei of binucleated lymphocytes induced by X-rays or colchicine was scored using the whole chromosome painting technique. The observed frequency of involvement in micronucleus formation was compared with the yield that would be expected theoretically, when the random participation of each chromosome is assumed. No difference was observed between the expected and observed inclusion of chromosome 2 or chromosome 7 into micronuclei after X-ray exposure (2.5 Gy). This was also the case for chromosome 2, but not for chromosome 7 after colchicine treatment (0.04/0.06 microgram/ml); chromosome 7 was detected approximately 1.5 times more frequently in micronucleus formation than would be expected from the assumption of a random distribution.

Aneuploidy↗

Origin of aneuploidy in relation to disturbances of cell-cycle progression. II: Cytogenetic analysis of various parameters in mouse bone marrow cells after colchicine or hydroquinone treatment.

The relationship between in vivo aneuploidy and cell-cycle perturbation induced by potential aneugens was investigated in mouse bone marrow cells. This work was performed within the framework of a research programme coordinated by the European Community to study the ability of 10 selected chemicals to induce aneuploidy in different systems. In this context, the effects of colchicine (COL) and hydroquinone (HQ) on cell-cycle progression, aneuploidy, polyploidy, micronucleus and sister chromatid exchange induction in mouse bone marrow cells after bromodeoxyuridine incorporation are reported. Hyperploidy and polyploidy were scored in metaphases of cells that had undergone only one division after treatment. Both chemicals induced cell-cycle lengthening, hyperploidy and micronuclei. The kinetics of hyperploidy induction by the two compounds differed in that COL was positive at 24 h, whereas HQ was positive 18 h after treatment. Only colchicine was positive for polyploidy induction and neither chemical induced sister chromatid exchange. These results are compared with similar data obtained after vinblastine (VBL) treatment. The results suggest that VBL and COL induce chromosome malsegregation via a mechanism associated with perturbations in the cell-cycle, whereas HQ induces aneuploidy independently of cell-cycle lengthening, possibly altering a chromosomal component of chromosome segregation rather than a spindle component.

Aneuploidy↗

Colchicine poisoning: case report of two homicides.

Deaths resulting from the oral ingestion of colchicine are occasionally associated with suicides and therapeutic toxicity. However, homicidal deaths in which this drug is used are extremely rare. Two homicides in which colchicine was used are reported.

Adult↗

Massive colchicine overdose: a report on the toxicity.

A case of an overdose of colchicine for suicidal purposes is presented. The main complications observed involved the hematopoietic, the gastrointestinal, the respiratory and the central nervous system. Heinz bodies were noticed in the red blood cells, a finding which had not been previously documented in patients with colchicine overdose. Despite intensive management the patient died on the thirteenth hospital day of central nervous system complications.

Adolescent↗

Beneficial effect of colchicine in a case of sclerosing cholangitis.

A patient with ulcerative colitis and primary sclerosis cholangitis confirmed by liver biopsy and endoscopic retrograde cholangiography presented with severely altered liver function tests. A month of steroid treatment for the colitis symptoms had no effect on the liver function tests, and colchicine, 1 mg/day, was added. After 3 months of this combined treatment, improvement of the liver function tests was noted and progressed to complete normalization of all liver function tests at the end of a 2-year period of follow-up. On further follow-up, the patient remained asymptomatic and with normal liver function tests for an additional 3 years. Further controlled studies would be worthwhile to evaluate the possibility of treatment of primary sclerosis cholangitis with colchicine with or without steroids.

Adult↗

Mesencephalic THmRNA-reduced expression by blocking axonal transport with colchicine.

Colchicine, an axonal transport blocking agent, was unilaterally injected in the medial forebrain bundle of rats. As early as 18 h after the injection a rapid decrease in TH-mRNA level was observed in the substantia nigra and the ventral tegmental area (SN/VTA) on the injected side. In contrast, TH protein levels remained stable for 48 h, and decreased later in both cells bodies and terminals (caudate/putamen). The number of TH-immunopositive cells in SN/VTA increased after colchicine equally in both sides, excluding a neurotoxic effect. These results suggest that TH gene expression is controlled by a retrogradely transported activating factor rather than by feedback inhibition by the end product, i.e. TH protein.

Animals↗

Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease.

Anti-inflammatory drugs may be useful in the treatment of Alzheimer disease (AD). In preparation for therapeutic trials, we conducted pilot feasibility studies of hydroxychloroquine alone and in combination with colchicine in subjects with AD. A total of 20 subjects with probable AD were treated with hydroxychloroquine 200 mg twice daily for 11 weeks, or hydroxychloroquine 200 mg twice daily plus colchicine 0.6 mg twice daily for 12 weeks; subjects were monitored for adverse medical, cognitive, or behavioral effects. Neither regimen caused adverse effects on cognitive or behavioral assessment scores. There were no significant side effects in subjects receiving hydroxychloroquine alone; 2 subjects receiving the two drugs together experienced diarrhea. We conclude that these regimens of anti-inflammatory therapy are well tolerated in subjects with AD, indicating the feasibility of large-scale therapeutic trials of these agents.

Aged↗